N Engl J Med 2019 Dec 19
Veliparib with First-Line Chemotherapy and as Maintenance Therapy in Ovarian Cancer.
Related Questions
Would you recommend PARP inhibitor maintenance for a patient with HR-proficient ovarian cancer with no targetable mutation, but with a favorable KELIM score and a significant clinical, radiographic, and serological response to platinum-based chemotherapy?
1 Answers
Mednet Member
Gynecologic Oncology · University of Pittsburgh
To date, the clinical trials that have included biomarkers for response to PARP inhibitors have shown that those with BRCA pathogenic variants appear to have the largest benefit followed by those with HRD tumors; however, these do not account for all the individuals who have disease that could benef...
What is your current practice for obtaining mutation status for a patient with newly diagnosed ovarian cancer?
3 Answers
Mednet Member
Gynecologic Oncology · Center of Hope
My current practice is to test all newly diagnosed epithelial ovarian cancer patients (includes fallopian tube and peritoneal) with both germline multigene and somatic multigene/NGS panels. Only recently have I adopted the practice of concurrent testing at diagnosis rather than basing the decision t...